Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q15166

UPID:
PON3_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q15166; A4D1H8; O75855; O76060; Q6IRU9; Q8IX97; Q9BZH9

BACKGROUND:
The enzyme Serum paraoxonase/lactonase 3, identified by the unique identifier Q15166, is known for its low activity towards organophosphate paraxon and high specificity for hydrolyzing lactones, including statin prodrugs and aromatic lactones. This specificity underlines its role in biochemical pathways involving these substrates.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serum paraoxonase/lactonase 3's enzymatic functions offers a promising avenue for therapeutic innovation. Given its proficiency in processing statin prodrugs and other lactones, there is potential for leveraging its activity in designing novel interventions for managing cholesterol levels and preventing cardiovascular diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.